Juzo Compression Sleeve and Glove for Breast Cancer

Phase-Based Progress Estimates
Breast Cancer+4 More
Juzo Compression Sleeve and Glove - Device
What conditions do you have?

Study Summary

This trial is testing whether a compression sleeve with an embedded sensor can help prevent lymphedema.

Eligible Conditions
  • Breast Cancer
  • Breast

Treatment Effectiveness

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: 1, 3, 6, 9 and 12 months

Month 12
Arm Volume
Questionnaire Completion
4 Weeks
Adherence rate to compression
Sensor Accuracy

Trial Safety

Trial Design

1 Treatment Group

Compression therapy
1 of 1
Experimental Treatment

40 Total Participants · 1 Treatment Group

Primary Treatment: Juzo Compression Sleeve and Glove · No Placebo Group · N/A

Compression therapyExperimental Group · 2 Interventions: Compression Sleeve Sensor, Juzo Compression Sleeve and Glove · Intervention Types: Device, Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1, 3, 6, 9 and 12 months

Who is running the clinical trial?

Olayan-Xefos Family Fund for Breast Cancer ResearchUNKNOWN
Massachusetts General HospitalLead Sponsor
2,673 Previous Clinical Trials
30,828,616 Total Patients Enrolled
77 Trials studying Breast Cancer
125,476 Patients Enrolled for Breast Cancer
Adele McKinnon Research Fund for Breast Cancer-Related LymphedemaUNKNOWN
Heinz Family FoundationUNKNOWN
2 Previous Clinical Trials
242 Total Patients Enrolled
2 Trials studying Breast Cancer
242 Patients Enrolled for Breast Cancer
Alphonse G Taghian, MD, PhDPrincipal InvestigatorMassachusetts General Hospital
1 Previous Clinical Trials
2,000 Total Patients Enrolled

Eligibility Criteria

Age 18+ · Female Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Eligible participants will read and comprehend English, with the ability to understand and the willingness to sign a written consent document.
You are female, >/= 18 years, who underwent BC surgery for invasive or in-situ carcinoma with unilateral axillary lymph node dissection (with or without contralateral prophylactic SLNB).

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 21st, 2021

Last Reviewed: October 11th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.